Denali Therapeutics Inc.(DNLI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

DNLI Denali Therapeutics Inc.

Trading 08-26 12:19:00 EDT

24.39

-0.54

-2.17%

High24.89	Low24.33	Vol249.43K
Open24.75	D1 Closing24.93	Amplitude2.25%
Mkt Cap3.90B	Tradable Cap3.68B	Total Shares159.85M
T/O6.11M	T/O Rate0.17%	Tradable Shares151.07M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"DNLI","market":"US","secType":"STK","nameCN":"Denali Therapeutics Inc.","latestPrice":24.39,"timestamp":1787761139046,"preClose":24.93,"halted":0,"volume":249428,"delay":0,"changeRate":-0.02166064981949455,"floatShares":151072166,"shares":159847403,"eps":-2.835349,"marketStatus":"Trading","change":-0.54,"latestTime":"08-26 12:19:00 EDT","open":24.75,"high":24.89,"low":24.33,"amount":6110763.260795999,"amplitude":0.022463,"askPrice":24.4,"askSize":106,"bidPrice":24.38,"bidSize":164,"shortable":3,"etf":0,"ttmEps":-2.835349,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787774400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1512709200000,"exchange":"NASDAQ","adjPreClose":24.93,"preHourTrading":{"tag":"盘前","latestPrice":24.71,"preClose":24.93,"latestTime":"09:29 EDT","volume":1770,"amount":43921.85969999999,"timestamp":1787750999999,"change":-0.22,"changeRate":-0.008825,"amplitude":0.075411},"postHourTrading":{"tag":"盘后","latestPrice":24.93,"preClose":24.93,"latestTime":"19:30 EDT","volume":27335,"amount":681458.57,"timestamp":1787700602599,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.544991,"impliedVol":0.3003,"impliedVolPercentile":0.0637},"requestUrl":"/m/hq/s/DNLI","defaultTab":"news","newsList":[{"id":"2662734161","title":"Denali Therapeutics Inc. : B. Riley Raises Target Price to $35 from $30","url":"https://stock-news.laohu8.com/highlight/detail?id=2662734161","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662734161?lang=en_us&edition=fundamental","pubTime":"2026-08-25 20:18","pubTimestamp":1787660332,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nFWN44M0I3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4535","DNLI","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662781491","title":"U.S. Research Roundup-Masco, Sherwin-Williams, Vulcan Materials","url":"https://stock-news.laohu8.com/highlight/detail?id=2662781491","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662781491?lang=en_us&edition=fundamental","pubTime":"2026-08-25 15:27","pubTimestamp":1787642845,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Masco, Sherwin-Williams, Vulcan MaterialsAug 25 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Masco","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nL8N44M0AY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXP","FAC","BKR","DAMD","ALB","AMD","IETC","TEK","FBIN","ACM","INSM","WMS","CSL","MLM","PTF","CLMT","GTLB","APMD","CURB","AMRZ","LEU","VMC","ACAD","JBTM","MRSH","SHW","KRO","GPN","KNF","EMSF","CHYM","AMAT","CLSE","FIS","FLNC","FMC","KDK","SMHX","MAS","AWI","BXP","ANAB","MU","FIVE","LRCX","MRVL","GTEK","DNLI","HON","DT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660743112","title":"Denali Therapeutics (DNLI) Could Be 42% Undervalued Following Its Earnings Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2660743112","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660743112?lang=en_us&edition=fundamental","pubTime":"2026-08-18 00:27","pubTimestamp":1786984065,"startTime":"0","endTime":"0","summary":"Denali Therapeutics earnings set the tone for investors\nDenali Therapeutics (DNLI) reported second quarter 2026 revenue of US$3.6 million, with a net loss of US$127.55 million and basic loss per share from continuing operations of US$0.68.\nSee our latest analysis for Denali Therapeutics.\nDenali Therapeutics shares currently trade at US$24.40, with a 90 day share price return of 34.73% and a year to date share price return of 49.97%. The 1 year total shareholder return of 64.64% contrasts with...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dnli/denali-therapeutics/news/denali-therapeutics-dnli-could-be-42-undervalued-following-i","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dnli/denali-therapeutics/news/denali-therapeutics-dnli-could-be-42-undervalued-following-i","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DNLI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657613161","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2657613161","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657613161?lang=en_us&edition=fundamental","pubTime":"2026-08-07 15:50","pubTimestamp":1786089008,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Outset Medical (OM) and Denali Therapeutics (DNLI) w...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-287?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-287?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4535","BK4548","DNLI","OM","BK4139","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657666668","title":"Earnings Flash (DNLI) Denali Therapeutics Posts Q2 Loss of $0.68, vs. FactSet Est of $0.51 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2657666668","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657666668?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:30","pubTimestamp":1786051829,"startTime":"0","endTime":"0","summary":"Earnings Flash (DNLI) Denali Therapeutics Posts Q2 Loss of $0.68, vs. FactSet Est of $0.51 Loss","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DNLI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657663771","title":"Denali Therapeutics Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657663771","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657663771?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:01","pubTimestamp":1786050093,"startTime":"0","endTime":"0","summary":"Denali Therapeutics Inc. reports results for the quarter ended June 30 - Earnings SummaryDenali Therapeutics Inc.DNLI.OQreported a quarterly adjusted loss of 68 cents per share for the quarter ended J","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N4433DR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4139","DNLI","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657657061","title":"Denali Q2 FY26 Net Loss Widens to $127.6 Million; Revenue Turns to $3.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657657061","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657657061?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:12","pubTimestamp":1786047121,"startTime":"0","endTime":"0","summary":"Denali Q2 FY26 net loss widens to $127.6 million; revenue turns to $3.6 millionDenali posted a GAAP net loss of $127.6 million, or $0.68 per share, for the quarter ended June 30, 2026.Revenue was $3.6","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDLbY4NkH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","LU2210149790.SGD","IE00BN0W2T93.GBP","BK4585","IE00B3QW5Z07.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","SG9999014013.SGD","DNLI","NDAQ","BK4548","SG9999014005.SGD","LU0314104364.USD","LU2095319765.USD","SG9999014039.USD","IE00BN0W2V16.EUR","BK4112","SG9999014021.USD","LU2210150020.SGD","BCDF","BK4588","IE00BN0W2W23.USD","BK4139","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657652798","title":"Denali Therapeutics Q2 Operating Expenses USD 134.145 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657652798","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657652798?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:02","pubTimestamp":1786046521,"startTime":"0","endTime":"0","summary":"BRIEF-Denali Therapeutics Q2 Operating Expenses USD 134.145 MillionAug 06 (Reuters) - Denali Therapeutics Q2 net income USD -127.553 million.Q2 basic EPS USD -0.68Q2 operating income USD -130.541 millionQ2 TOTAL REVENUE USD 3.6 MILLION","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXHQLTJG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNLI","BK4548","BK4535","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657652789","title":"Denali Therapeutics - Projects Q3 2026 Avlayah Net Product Revenue of $10 Mln-$12 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2657652789","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657652789?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:01","pubTimestamp":1786046462,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXHQLTJG:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4548","BK4139","BK4535","DNLI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657524416","title":"Denali Therapeutics Q2 Basic EPS USD -0.68","url":"https://stock-news.laohu8.com/highlight/detail?id=2657524416","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657524416?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:01","pubTimestamp":1786046462,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXHQLTJG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DNLI","BK4535","BK4548","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657652280","title":"Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2657652280","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657652280?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:01","pubTimestamp":1786046461,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUAYKCRB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4548","DNLI","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656372691","title":"Denali Therapeutics treatment of frontotemporal dementia granted orphan status","url":"https://stock-news.laohu8.com/highlight/detail?id=2656372691","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656372691?lang=en_us&edition=fundamental","pubTime":"2026-08-03 22:00","pubTimestamp":1785765655,"startTime":"0","endTime":"0","summary":"Denali Therapeutics (DNLI)’ progranulin replacement therapy was granted FDA orphan designation as a treatment of frontotemporal dementia, according...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/denali-therapeutics-treatment-of-frontotemporal-dementia-granted-orphan-status-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/denali-therapeutics-treatment-of-frontotemporal-dementia-granted-orphan-status-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4139","LENZ","LABU","DNLI","BK4548","BK4007","BK4535","BK4539","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170304034","title":"Earning Preview: Denali Therapeutics Inc. Q2 revenue is expected to increase by 125.86%, institutional views are mostly positive","url":"https://stock-news.laohu8.com/highlight/detail?id=1170304034","media":"Earnings Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170304034?lang=en_us&edition=fundamental","pubTime":"2026-07-31 12:47","pubTimestamp":1785473258,"startTime":"0","endTime":"0","summary":"Abstract Denali Therapeutics Inc. will release its quarterly results on August 06, 2026 Post Market; this preview highlights consensus expectations on revenue, EBIT, EPS, and margins, together with...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Earning Preview: Denali Therapeutics Inc. Q2 revenue is expected to increase by 125.86%, institutional views are mostly positive","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNLI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654900802","title":"Denali Therapeutics Sells Priority Review Voucher for $195 Million Gross Proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=2654900802","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654900802?lang=en_us&edition=fundamental","pubTime":"2026-07-28 18:04","pubTimestamp":1785233083,"startTime":"0","endTime":"0","summary":"Denali Therapeutics sells priority review voucher for $195 million gross proceedsDenali Therapeutics closed the sale of its Rare Pediatric Disease Priority Review Voucher on July 27, 2026.Transaction ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nNDLNFkWk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4548","DNLI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654040929","title":"Denali Therapeutics Schedules Quarterly Results Release and Conference Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2654040929","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654040929?lang=en_us&edition=fundamental","pubTime":"2026-07-28 04:01","pubTimestamp":1785182488,"startTime":"0","endTime":"0","summary":"Denali Therapeutics schedules quarterly results release and conference callDenali Therapeutics schedules second-quarter 2026 results release for Aug. 6, 2026.Conference call, webcast set for Aug. 6, 2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nNDL1lkqJ4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","DNLI","IE00BN0W2W23.USD","BK4548","BK4112","BCDF","SG9999014039.USD","IE00BN0W2V16.EUR","BK4139","BK4535","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","SG9999014005.SGD","LU2095319765.USD","SG9999014013.SGD","LU2210150020.SGD","SG9999014021.USD","IE00BKPKM429.USD","LU0314104364.USD","IE00BGHQF748.EUR","NDAQ","BK4585","BK4588","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653717278","title":"Denali Therapeutics (DNLI) Stock May Trade At A 12% Premium Following AAIC 2026 Plenary News","url":"https://stock-news.laohu8.com/highlight/detail?id=2653717278","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653717278?lang=en_us&edition=fundamental","pubTime":"2026-07-23 15:27","pubTimestamp":1784791653,"startTime":"0","endTime":"0","summary":"Denali Therapeutics stock has delivered a 63.4% return over the past year. However, both the Discounted Cash Flow (DCF) intrinsic value estimate and the market multiples currently point to the shares trading at a premium rather than at a clear discount.\n\nOver the last 12 months, a 63.4% gain has rewarded Denali Therapeutics shareholders. This raises the question of how much future upside is already reflected in the price.\nExcitement around Denali Therapeutics' progress in delivering biologic...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dnli/denali-therapeutics/news/denali-therapeutics-dnli-stock-may-trade-at-a-12-premium-fol","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dnli/denali-therapeutics/news/denali-therapeutics-dnli-stock-may-trade-at-a-12-premium-fol","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4535","BK4585","BK4588","BK4110","BK4139","DCF","DNLI","BK4548","SPHQ","AAIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651464549","title":"Analysts’ Top Healthcare Picks: Denali Therapeutics (DNLI), Celcuity (CELC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2651464549","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651464549?lang=en_us&edition=fundamental","pubTime":"2026-07-15 22:40","pubTimestamp":1784126407,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Denali Therapeutics (DNLI) and Celcuity (CELC) with ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-denali-therapeutics-dnli-celcuity-celc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-denali-therapeutics-dnli-celcuity-celc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","BK4548","BK4137","BK4139","LU0029874061.USD","BK4581","LABU","DNLI","LU0128526141.USD","BK4585","HCSG","BK4535","XLV","CELC","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651310456","title":"Denali Therapeutics falls -12.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651310456","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651310456?lang=en_us&edition=fundamental","pubTime":"2026-07-14 22:05","pubTimestamp":1784037910,"startTime":"0","endTime":"0","summary":"Denali Therapeutics (DNLI) is down -12.4%, or -$3.28 to $23.20. Published first on TheFly – the ultimate source for real-time, market-moving breaki...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/denali-therapeutics-falls-12-4-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/denali-therapeutics-falls-12-4-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4535","BK4007","LENZ","BK4539","BK4139","DNLI","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651060531","title":"Biogen's Alzheimer's Drug Lowers Toxic Protein, but Results were Mixed","url":"https://stock-news.laohu8.com/highlight/detail?id=2651060531","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651060531?lang=en_us&edition=fundamental","pubTime":"2026-07-14 21:15","pubTimestamp":1784034900,"startTime":"0","endTime":"0","summary":"Biogen's Alzheimer's drug lowers toxic protein, but results were mixedAt 60 mg, diranersen slowed decline 26% on CDR-SB versus placeboLowest dose reduced decline on five of six common Alzheimer's asse","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260714:nL1N43A0RQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMED","BIIB","BK4548","IE00B19Z9P08.USD","LU0320765992.SGD","LU0109394709.USD","LU0234570918.USD","IE00B894F039.SGD","BK4585","BK4139","DNLI","BK4588","BK4532","IE00B19Z9Z06.USD","PBE","BK4535","BK4533","VYGR","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651148690","title":"Jefferies Keeps Their Buy Rating on Denali Therapeutics (DNLI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2651148690","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651148690?lang=en_us&edition=fundamental","pubTime":"2026-07-13 23:15","pubTimestamp":1783955714,"startTime":"0","endTime":"0","summary":"Jefferies analyst maintained a Buy rating on Denali Therapeutics today and set a price target of $40.00. Currently, the analyst consensus on Denali...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jefferies-keeps-their-buy-rating-on-denali-therapeutics-dnli-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jefferies-keeps-their-buy-rating-on-denali-therapeutics-dnli-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DNLI"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.denalitherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0255},{"period":"1month","weight":0.0788},{"period":"3month","weight":0.2335},{"period":"6month","weight":0.1639},{"period":"1year","weight":0.6012},{"period":"ytd","weight":0.51}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.0365},{"period":"3month","weight":0.0206},{"period":"6month","weight":0.1111},{"period":"1year","weight":0.1921},{"period":"ytd","weight":0.1232}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":0.068767},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.02262},{"month":3,"riseRate":0.222222,"avgChangeRate":-0.087803},{"month":4,"riseRate":0.555556,"avgChangeRate":0.007711},{"month":5,"riseRate":0.777778,"avgChangeRate":0.055944},{"month":6,"riseRate":0.666667,"avgChangeRate":0.078033},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.052711},{"month":8,"riseRate":0.666667,"avgChangeRate":0.06915},{"month":9,"riseRate":0.5,"avgChangeRate":0.021936},{"month":10,"riseRate":0.375,"avgChangeRate":-0.037447},{"month":11,"riseRate":0.625,"avgChangeRate":0.13715},{"month":12,"riseRate":0.375,"avgChangeRate":0.011033}],"exchange":"NASDAQ","name":"Denali Therapeutics Inc.","nameEN":"Denali Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Denali Therapeutics Inc.(DNLI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Denali Therapeutics Inc.(DNLI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Denali Therapeutics Inc.,DNLI,Denali Therapeutics Inc.股票,Denali Therapeutics Inc.股票老虎,Denali Therapeutics Inc.股票老虎国际,Denali Therapeutics Inc.行情,Denali Therapeutics Inc.股票行情,Denali Therapeutics Inc.股价,Denali Therapeutics Inc.股市,Denali Therapeutics Inc.股票价格,Denali Therapeutics Inc.股票交易,Denali Therapeutics Inc.股票购买,Denali Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Denali Therapeutics Inc.(DNLI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Denali Therapeutics Inc.(DNLI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}